// App-Quantinova.ai

121 : ERG Intragenic Deletion Characterizes a Distinct Oncogenic Subtype of B-Cell Precursor Acute Lymphoblastic Leukemia with a Favourable Outcome Despite Frequent IKZF1 Deletions

Researchers

Presenter

  • Andre Baruchel

Principal Investigators

  • Alina Ferster

  • Seraphine Rossi

  • Sandrine Girard

  • Nicole Dastugue

  • Marleen Bakkus

  • Stefan Suciu

  • Yves Benoit

  • Yves Bertrand

  • Jean so ULIER

  • Helene Cave

  • Aurelie Caye

  • Ahleme Khemiri

  • Lucie Hernandez

  • Emmanuelle Kabongo

  • Thierry Leblanc

  • Karima Yakouben

  • Genevieve Plat

  • Vitor Costa

Medical Centers

  • Haematology Laboratory, Saint-Louis Hospital, APHP, Paris, France

  • Department of Pediatric Hematology-Immunology, Robert Debre Hospital, Paris, France

  • Department of Radiation Oncology, Ghent University Hospital, Gent, Belgium

  • Molecular Hematology laboratory, UZ Brussels, Brussels, Belgium

  • Dept. of Hemato-oncologie pediatrique, Children's University Hospital Reine Fabiola, Brussels, Belgium

  • Department of Genetics, Robert Debre Hospital, APHP, Paris, France

  • EORTC Headquarters, Brussels, Belgium

  • Department of Medical Oncology, Portuguese Oncology Institute, Porto, Portugal

  • Hematology laboratory, IHOP, Lyon, France

  • Hematology, University Hospital of Toulouse, Toulouse, France

  • Pediatric Hematology Department, IHOP and Claude Bernard University, Lyon, France

  • Dept. of Pediatric Hematology, Robert Debre hospital, APHP, Paris, France

Locations

  • France

  • Portugal

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Acute myelocytic leukemia

  • Solid malignancies

Biomarkers

  • ETS transcription factor ERG

  • ETV6-RUNX1

  • Histone-lysine N-methyltransferase 2A

Drug/Treatment

  • N/A

Outcome

  • N/A


Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim